Palladium One Corporate Update

Posted on August 17, 2021 by Admin

Palladium One Corporate Update

August 17, 2021 – Toronto, Ontario –Palladium One Mining (“Palladium One” or the “Company”) (TSXV: PDM, FRA: 7N11, OTC: NKORF) is pleased to provide this corporate update which highlights the current exploration status of our two primary projects, namely the LK PGE-Cu-Ni Project in Finland and the Tyko Copper-Nickel Project in Ontario, Canada. In addition, we are pleased to provide the key objectives of the Company over the coming months.

“With a cash balance of $15 million (unaudited) as at July 31, 2021, the Company is well funded to advance planned activities for the foreseeable future.” said Derrick Weyrauch, President and CEO.

Key Objectives (Milestones)

LK Platinum Group Element-Copper-Nickel Project, Finland

Resource definition drilling at Kaukua and the western portion of Kaukua South (“Kaukua Areas”) is scheduled for completion mid-September 2021. (Figure 1)
A NI43-101 compliant resource estimate for the Haukiaho zone, located 10 kilometers south of Kaukua, is scheduled for completion in Q3 2021.
Phase II metallurgical testing of the Kaukau Areas is underway and scheduled for completion before year end.
An updated NI43-101 compliant resource for the Kaukua Areas is scheduled for completion at year end (December 2021/January 2022).
A Preliminary Economic Assessment (“PEA”) is planned for mid-2022.
Step out drilling targeting the recently announced Induced Polarization (IP) anomaly to the west of Kaukua is scheduled to be drill tested starting September 2021. (Figure 1) (see news release dated July 7, 2021).
Assay labs continue to struggle with timely delivery of results due to an industry wide high volume of activity.
Assay results for 38 drill holes remain outstanding, while results have been released for 78 drill holes.

Tyko Copper-Nickel Project, Ontario, Canada

Drilling has resumed on the Smoke Lake zone, following a major drill breakdown and early spring thaw.
1. Four holes have been completed from a planned seven-hole program.
2. The objective is to find the source of the high-grade mineralization which produced intersections up to 9.9% Ni_Eq over 3.8 metres at surface (8.2 % Ni, 2.9 % Cu, 0.1 % Co, 0.6 g/t Pd, 0.5 g/t Pt), (see press release January 19, 2021)
3. Previously, 28 drill holes defined a shallow 350-meter mineralized strike length at the Smoke Lake zone.
4. Exploration drilling is targeting:
  1. Down plunge extensions of known mineralization.
  2. A large inverted magnetic high located below the Smoke Lake zone (Figure 2) will be tested by a 900-meter geophysics platform hole. The magnetic high may represent a significant accumulation of ultramafic rocks, potentially representing the source of remobilized / injected massive sulphides found at surface.
  3. After completion of the 900-meter deep hole, a Borehole Electromagnetics (“BHEM”) survey is planned to help determine the possible presents of massive sulphide mineralization at depth.
A 3,100-line kilometer VTEM geophysics survey has been completed over the entire Tyko property, the results of which are expected shortly.
The summer field program is well underway, crews are on their second rotation and beginning to explore the newly expanded Tyko Property (see news release July 27, 2021).
1. To date over 1,300 soil samples have been collected for analysis, while results are pending.

Figure 1. Historic and current drilling in the Kaukua and Western portion of the Kaukau South area. Background is IP Chargeability.

Figure 2. Isometric view of the Smoke Lake zone area looking north-northwest showing 2020 drill holes and inverted drone based high-resolution magnetics.

Qualified Person

The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43-101.

About Palladium One

Palladium One Mining Inc. is an exploration company targeting district scale, platinum-group-element (PGE)-copper-nickel deposits in Finland and Canada. Its flagship project is the Läntinen Koillismaa or LK Project, a palladium-dominant platinum group element-copper-nickel project in north-central Finland, ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. Exploration at LK is focused on targeting disseminated sulfides along 38 kilometers of favorable basal contact and building on an established NI 43-101 open pit resource.

ON BEHALF OF THE BOARD
“Derrick Weyrauch”
President & CEO, Director

For further information contact:
Derrick Weyrauch, President & CEO
Email: info@palladiumoneinc.com

Neither the TSX Venture Exchange nor its Market Regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release is not an offer or a solicitation of an offer of securities for sale in the United States of America. The common shares of Palladium One Mining Inc. have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

Information set forth in this press release may contain forward-looking statements. Forward-looking statements are statements that relate to future, not past events. In this context, forward-looking statements often address a company’s expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in palladium and other commodity prices; title matters; environmental liability claims and insurance; reliance on key personnel; the absence of dividends; competition; dilution; the volatility of our common share price and volume; and tax consequences to Canadian and U.S. Shareholders. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

Why Michael Burry has Better Opportunity Than Cathie Wood

Posted on August 17, 2021 by Admin

Michael Burry vs Cathie Wood is Not an Even Competition

With proof that Michael Burry has shorted tens of millions of one of Cathie Wood’s Ark ETFs, the headlines are asking, “who is right, the hedge fund manager or popular tech fund manager?” Although there may be a conflict of forecasts between these two very successful money managers, the role and flexibility of each are very different.

Burry and His Position

In a filing made available Monday (August 16), Burry’s Scion Asset Management disclosed it held Put options on 235,500 shares of Ark Investments, Innovation ETF (ARKK). At the end of the second quarter, these bets against Cathie Wood’s renowned Ark Investments were valued at $30.8 million dollars. The position is essentially a speculative play that expects that the value of the ETF will drop before the expiration date.

Burry, who is 50 years old, is best known for his being portrayed in the movie of the real-life drama where he managed to massively short the subprime mortgage market beginning in 2005. The positions paid off fabulously years later. As per Michael Lewis’ book, The Big Short from which the movie of the same name is based, the nature of Scion’s positions is long-term as they’re scaled into and play out over time — long before a trend takes root. As an individual, Burry is never seen on TV or any other promotional forum. The few interviews have been via Bloomberg Messenger with Bloomberg reporters, and he will at times share his thoughts in Twitter posts.

Wood’s Stature

Wood, who is 65 years old, founded Ark Investments in 2014 on the idea of actively traded funds based on disruptive innovation. Ticker symbol $AARK is one of the actively managed funds she oversees at her company. The year 2020 was especially good for many of her funds including AARK. This gave her much to talk about last year as a regular on CNBC and other channels, she has managed to develop her own celebrity status. Ms. Wood and her funds have an almost cult following, however, the high returns of last year have not followed through so far in 2021.

Source: Bloomberg Terminal (8/17/21)

As the successes of both Wood and Burry place them on investor’s radar, the story of this massive short against technology has gained attention. The truth is, the two are in very different positions. Although they may both try to maximize returns on the funds they manage, they are not even in the same ring or constrained by the same rules.

Is This a Fair “Fight”

As the Chief Investment Officer overseeing the funds within her company, Cathie Wood is bound by the SEC filed prospectus and other documents guiding each of Ark’s ETFs. Dr. Michael J. Burry, for his part, is an individual investor and runs a hedge fund without the same restrictions as a publicly-traded ETF. Should Scion decide that a particular investment class is not going to add value to the overall position, Scion is not under any obligation to own the sector. If Burry sees fit as manager, he may enter a position that is triple leveraged short. This flexibility is important to understand.

Source: Page 1 and 2 of AARK Summary Prospectus

ETFs and other mutual funds are generally used by investors seeking broad exposure to a sector, index, or particular investment style. The onus is on the end investor of the fund (not the manager) to reduce their position if they are bearish. Management is obligated to continue to follow the style the investors have placed funds in; within the margins of the prospectus there is some leeway (see AARK document above); however, the overall marching orders remain the same.

This is why fund performance is judged within sectors and indices. The fund managers’ comparative benchmarks are almost always within the investment style, not versus what was available in unrelated investments.

Another advantage investors with complete flexibility have over fund managers is that when performance falters in a fund sector, money flows out of the funds, this often forces the manager to sell when values are low. When sectors are hot, new money flows in, putting this money to work places the manager in the tricky position of deploying new funds in companies that may already be near their peak. Individuals and money managers such as Burry are not presented with performance-limiting cash flow which waters down return on public funds.

Take-Away

Hedge fund managers and individual investors have more leeway than fund managers of publicly offered funds that are guided by a prospectus and other SEC-related documents. ETFs and other funds are popular when an entire sector is moving up. When companies within that sector or index begin to weigh down performance, those that can hand select equity positions for their portfolio, and even go short, have far more opportunities.

Exploring opportunities and discovering growth companies is how Channelchek serves its readers. Take a moment to register for daily updates and research designed to provide ideas and insight to small and microcap investors.

Paul
Hoffman

Managing Editor, Channelchek

Suggested Reading:

Index Funds May Still Fall Apart Over Time

Is the Index Bubble Michael Burry Warned us About Still Looming?

Michael Burry Tweets Advice on Cryptocurrency

Michae Burry Says Covid Cure Worse Than Disease

Sources:

https://www.sec.gov/Archives/edgar/data/1649339/000156761921015632/xslForm13F_X01/form13fInfoTable.xml?modtag=djemBestOfTheWeb&mod=djem_b_Feature_8172021%2063115%20AM

https://en.wikipedia.org/wiki/Cathie_Wood#:~:text=In%202014%2C%20after%20her%20idea,company%20and%20founded%20Ark%20Invest.

https://etfs.ark-funds.com/hubfs/1_Download_Files_ETF_Website/Prospectuses/ARKK_Summary_Prospectus.pdf

https://www.scionasset.com/

Stay up to date. Follow us:

Noble Capital Markets Uranium Power Players Investor Forum – Presenting Companies

Posted on August 17, 2021 by Admin

Noble Capital Markets Uranium Power Players Investor Forum
August 31, 2021

View the Power Players Summit Presentations Here

View the Official Power Players Summit Book Here

The Noble Uranium Power Players Investor Forum is a virtual conference bringing together leading companies involved in the exploration and production of uranium. Demand for uranium is growing as idled nuclear plants are restarted and new plants are being built. At the same time, uranium supply is decreasing as mines run out of uranium and new potential mines are not being developed due to low uranium pricing. Many experts believe uranium prices will rise in upcoming years although the timing and magnitude of the increase are unknown. Our panel of management teams will discuss their respective company’s roles in the revitalization of uranium mining. Noble Capital Markets senior uranium analyst, Michael Heim, will guide the companies through a question and answer session following each presentation.

The Investor Forum is free and open to all registered users of Channelchek. Registration is fast and free. Not already a member? Use the link below to register now so you’re ready to view the Investor Forum presentations on August 31.

On Mobile? Register for Channelchek here!

Click the logos for more information on the presenting companies

Azincourt Energy (AZURF)	Blue Sky Uranium (BKUCF)
CanAlaska Uranium (CVVUF)	enCore Energy (ENCUF)
Energy Fuels (UUUU)	GoviEx Uranium (GVXXF)
Peninsula Energy (PENMF)	Standard Uranium (STTDF)

Schwazze Announces Second Quarter Results

Posted on August 17, 2021 by Admin

Schwazze Announces Second Quarter Results

Revenue Increases 467% to $30.7 Million Compared to $5.4 Million in Q1 2020

Adjusted EBITDA is $10.0 Million, 32.6% of Revenue

On Track to Meet Guidance of Annual Projected Revenue of Approximately $110 Million – $125 Million Annual Projected Adjusted EBITDA $30 Million – $36 Million

Conference Call and Webcast Scheduled for Today – 4:30 pm ET

DENVER, Aug. 16, 2021 /PRNewswire/ – Schwazze, (OTCQX: SHWZ) (“Schwazze” or the “Company”), announced financial results for its second quarter year ended June 30, 2021 (“Q2 2021”).

Financial Summary for Q2 2021:

Revenues of $30.7 million grew 467% over Q2 2020 and 58.9% over Q1 2021
Gross Margin of $14.9 million was 48.5%, 576 bps better than Q2 2020 and 1,099 bps over Q1 2021
Adjusted EBITDA of $10.0 million was 32.6% of revenue, 239 bps above Q1 2021
Net Income was $4.4 million or $0.08 Diluted Earnings per share compared to a Net Loss in Q2 2020 of ($6.6) million or ($0.16) Diluted Net Loss per share and compared to a Net Loss in Q1 2021 of ($3.6) million or ($0.09) Diluted Net Loss per share
Cash Flow from operations for the six-month period was $1.4 million
Same store sales of the seventeen Star Buds dispensaries when compared to last year were $21.5M up 16%.
- Average basket size was $61.04 up 6.4%
- Recorded customer visits were 357,056 up 8.9%
  Note: Schwazze did not own all the assets in 2020 and are using unaudited numbers for this comparison.

Other Q2 2021 Highlights
Acquisition of Southern Colorado Growers: The Company announced on June 1, 2021, that it had entered into a transaction to acquire the assets of Southern Colorado Growers in Huerfano County, Colorado (transaction closed July 22, 2021). The acquisition includes 36 acres of land with outdoor cultivation capacity, as well as indoor, greenhouse, and hoop house cultivation facilities and equipment. This purchase expanded Schwazze’s footprint in Colorado, is the Company’s first major move into cultivation, and will provide high-end, premium cannabis directly to its Star Buds dispensaries as well as significant production of biomass for its PurpleBee’s extraction and manufacturing facility.

Acquisition of Drift Dispensaries: The Company announced that it had signed definitive documents to acquire the assets of BG3 Investments, LLC dba Drift which consists of two marijuana retail stores located in Boulder, Colorado, bringing the total number of Schwazze Colorado dispensaries to nineteen.

“We have continued to see strong revenue growth over last year and are pleased with our adjusted EBITDA results,” stated Justin Dye, CEO of Schwazze. “Furthermore, we continue to be encouraged with our retail results, which saw growing sales by 68.9% on a two-year basis. Wholesale results, led by PurpleBee’s distillate also had another record-breaking sales quarter. We continue to execute on our retail and manufacturing playbook with excellent results and with the addition of Southern Colorado Growers and Drift, we look forward to continuing to add to our portfolio of companies.”

Second Quarter 2021 Revenue
Total revenue was $30.7 million during the three months ended June 30, 2021, compared to $5.4 million during the same period in 2020 and represents an increase of approximately 467%. Retail sales grew to $21.5 million over the quarter from $0.7 million dollars the previous year and wholesale operations revenue increased to $9.2 million from $4.1 million compared to the same period last year. Other sales decreased to $0.02 million from $0.59 million due to a reduced focus on consulting. The increase in retail and wholesale revenue is attributed to the acquisition of Mesa Organics in April 2020 and the completion of the acquisition of Star Buds in March 2021.

Total cost of goods and services were $15.8 million during the three months ended June 30, 2021, compared to $3.1 million during the same period in 2020. This increase was due to improved sales from our retail and wholesale operations.

Gross profit increased to $14.9 million during the three months ended June 30, 2021, compared to $2.3 million during the same period in 2020. Gross profit margin increased as a percentage of revenue from 48.5% to 42.7% mostly driven by the strength of Star Buds acquisition, and our consolidated purchasing approach.

Total operating expenses were $10.5 million during the second quarter compared to $8.7 million during the same period in 2020. The higher expenses were due to increased selling, general and administrative expenses, and salaries from the addition of the dispensaries.

Q2 2021 net income was $4.4 million, or a gain of approximately $0.10 per share on a basic weighted average, as compared to net loss of $6.6 million, or a loss of approximately $0.16 per share on a basic weighted average during the three months ended June 30, 2020.

Q2 2021 adjusted EBITDA was $10.0 million, representing 32.6% of revenue. This is derived from Operating Income and adjusting one-time expenses, merger and acquisition and capital raising costs, non-cash related compensation costs, and depreciation and amortization. See the financial table for Adjusted EBITDA below for details for Q2 2021 adjustments.

During the two quarters, the Company generated positive operating cash flow of $1.4 million and $19.9 million in total cash flow for the first two quarters with $21.1 million in cash and cash equivalents at the end of Q2 2021.

Nancy Huber, CFO for Schwazze commented, “We continue to generate operating cash flows from our acquired businesses. This quarter we used that cash flow to make strategic inventory purchases for third quarter usage.”

2021 Guidance
The Company is reiterating its 2021 guidance which excludes transactions that are announced but not closed. Annual revenue guidance is $110 million to $125 million and projected annual adjusted EBITDA from $30 million to $36 million.

Adjusted EBITDA represents income (loss) from operations, as reported, before tax, adjusted to exclude non-recurring items, other non-cash items, including stock-based compensation expense, depreciation, and amortization, and further adjusted to remove acquisition related costs, and other one-time expenses, such as severance. The Company uses adjusted EBITDA as it believes it better explains the results of its core business. The Company has not reconciled guidance for adjusted EBITDA to the corresponding GAAP financial measure because it cannot provide guidance for the various reconciling items. The Company is unable to provide guidance for these reconciling items because it cannot determine their probable significance, as certain items are outside of its control and cannot be reasonably predicted. Accordingly, a reconciliation to the corresponding GAAP financial measure is not available without unreasonable effort.

Q2 2021 Webcast
Investors and stakeholders may participate in the conference call by dialing 416 764 8650 or by dialing North American toll free 888-664-6383 or listen to the webcast from the Company’s website at https://ir.schwazze.com. The webcast will be available on the Company’s website and on replay until August 30, 2021, and may be accessed by dialing 888 390 0541 / Code 605725#.

Following their prepared remarks, Chief Executive Officer, Justin Dye and Chief Financial Officer, Nancy Huber will answer investor questions. Investors may submit questions in advance or during the conference call itself through the weblink: https://produceredition.webcasts.com/starthere.jsp?ei=1481988&tp_key=212e8e52ee. This weblink has been posted to the Company’s website and will be archived on the website. All Company SEC filings can also be accessed on the Company website at https://ir.schwazze.com/sec-filings.

About Schwazze
Schwazze (OTCQX: SHWZ) is building the premier vertically integrated cannabis company in Colorado and plans to take its operating system to other states where it can develop a differentiated leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices. Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc.

Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth.

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED BALANCE SHEETS
Expressed in U.S. Dollars

All accompanying notes to the financial statements can be found within the SEC Form 10-Q filed on August 16, 2021

	June 30, 2021		December 31, 2020
	(Unaudited)		(Audited)
Assets
Current assets
Cash and cash equivalents	$	21,130,769	$	1,231,235
Accounts receivable, net of allowance for doubtful accounts		3,204,941		1,270,380
Accounts receivable – related party		–		80,494
Inventory		9,182,942		2,619,145
Note receivable – current, net		144,223		–
Notes receivable – related party		–		181,911
Prepaid expenses		1,865,138		614,200
Total current assets		35,528,013		5,997,365
Non-current assets
Fixed assets, net accumulated depreciation of $1,291,349 and $872,579, respectively		3,476,546		2,584,798
Goodwill		41,505,944		53,046,729
Intangible assets, net accumulated amortization of $4,553,827 and $200,456, respectively		94,861,253		3,082,044
Marketable securities, net of unrealized gain (loss) of $221,257 and $(129,992), respectively		498,039		276,782
Note receivable – noncurrent, net		71,667		–
Accounts receivable – litigation		3,063,968		3,063,968
Other noncurrent assets		419,472		51,879
Operating lease right of use assets		3,934,370		2,579,036
Total non-current assets		147,831,259		64,685,236
Total assets	$	183,359,272	$	70,682,601
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	2,335,217	$	3,508,478
Accounts payable – related party		40,323		48,982
Accrued expenses		10,279,124		2,705,445
Derivative liabilities		436,554		1,047,481
Deferred revenue		–		50,000
Notes payable – related party		–		5,000,000
Total current liabilities		13,091,218		12,360,386
Long-term liabilities
Long term debt		54,250,000		13,901,759
Lease liabilities		4,078,375		2,645,597
Total long-term liabilities		58,328,375		16,547,356
Total liabilities		71,419,593		28,907,742
Shareholders’ equity
Common stock $0.001 par value. 250,000,000 authorized, 42,925,303 shares issued and 42,408,259 outstanding as of June 30, 2021 and 42,601,773 shares issued and 42,169,041 outstanding as of December 31, 2020, respectively.		42,925		42,602
Preferred stock $0.001 par value. 10,000,000 authorized. 87,266 shares issued and outstanding as of June 30, 2021 and 19,716 shares issued and outstanding as of December 31, 2020, respectively.		87		20
Additional paid-in capital		158,787,183		85,357,835
Accumulated deficit		(45,373,480)		(42,293,098)
Common stock held in treasury, at cost, 517,044 shares held as of June 30, 2021 and 432,732 shares held as of December 31, 2020.		(1,517,036)		(1,332,500)
Total shareholders’ equity		111,939,679		41,774,859
Total liabilities and stockholders’ equity	$	183,359,272	$	70,682,601

See accompanying notes to the financial statements

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
For the Three Months Ended June 30, 2021, and 2020
Expressed in U.S. Dollars


	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	(Unaudited)		(Unaudited)		(Unaudited)		(Unaudited)
Operating revenues
Retail	$	21,525,816	$	732,457	$	33,342,016	$	732,457
Wholesale		9,186,181		4,106,197		16,632,445		6,635,128
Other		16,844		585,675		94,494		1,259,878
Total revenue		30,728,841		5,424,329		50,068,955		8,627,463
Cost of goods and services
Cost of goods and services		15,826,341		3,106,686		27,913,451		5,255,221
Total cost of goods and services		15,826,341		3,106,686		27,913,451		5,255,221
Gross profit		14,902,500		2,317,643		22,155,504		3,372,242
Operating Expenses
Selling, general and administrative expenses		4,797,495		1,088,479		7,987,134		1,755,398
Professional services		1,519,016		2,371,743		3,714,124		3,620,731
Salaries		2,992,055		2,098,291		4,861,413		4,095,327
Stock based compensation		1,153,018		3,109,091		2,636,824		4,361,822
Total operating expenses		10,461,584		8,667,604		19,199,494		13,833,278
Income (loss) from operations		4,440,916		(6,349,961)		2,956,010		(10,461,036)
Other income (expense)
Interest income (expense), net		(1,713,770)		(11,447)		(2,675,053)		36,595
Gain on forfeiture of contingent consideration		–		–		–		1,462,636
Unrealized gain (loss) on derivative liabilities		1,864,741		(348,535)		610,927		843,428
Other income (expense)		–		32,621		–		32,621
Gain (loss) on sale of assets		–		–		292,479		–
Unrealized gain (loss) on investments		6,627		81,615		221,257		110,739
Total other income (expense)		157,598		(245,746)		(1,550,390)		2,486,019
Provision for income tax (benefit) expense		228,474		–		685,088		–
Net income (loss)	$	4,370,041	$	(6,595,707)	$	720,532	$	(7,975,017)
Earnings (loss) per share attributable to common shareholders:
Basic earnings (loss) per share	$	0.10	$	(0.16)	$	0.02	$	(0.20)
Diluted earnings (loss) per share	$	0.08	$	(0.16)	$	0.01	$	(0.20)
Weighted average number of shares outstanding – basic		42,332,144		41,568,147		42,286,168		40,742,462
Weighted average number of shares outstanding – diluted		53,975,521		41,568,147		53,886,727		40,742,462

Comprehensive income (loss)	$	4,370,041	$	(6,595,707)	$	720,532	$	(7,975,017)

See accompanying notes to the financial statements

MEDICINE MAN TECHNOLOGIES, INC.
STATEMENT OF CASH FLOWS (UNAUDITED)
For the Three Months Ended June 30, 2021 and 2020
Expressed in U.S. Dollars


	For the Six Months Ended June 30,
	2021		2020
Cash flows from operating activities
Net income (loss) for the period	$	720,532	$	(7,975,017)
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization		4,807,147		94,269
Gain on forfeiture of contingent consideration		–		–
(Gain) loss on change in derivative liabilities		(610,927)		(2,306,064)
(Gain) loss on investment, net		(221,257)		(110,739)
(Gain) loss on sale of asset		(292,479)		–
Stock based compensation		2,636,824		4,361,822
Changes in operating assets and liabilities
Accounts receivable		(1,854,067)		780,772
Inventory		(3,368,807)		445,345
Prepaid expenses and other current assets		(1,250,938)		107,417
Other assets		(367,593)		(41,879)
Operating lease right of use assets and liabilities		77,444		16,773
Accounts payable and other liabilities		1,169,537		575,153
Deferred Revenue		(50,000)		–
Income taxes payables		–		(1,940)
Net cash provided by (used in) operating activities		1,395,416		(4,054,088)

Cash flows from investing activities
Purchase of fixed assets – net		(1,203,180)		(593,785)
Cash consideration for acquisition of business		(66,082,072)		(2,609,500)
Collection (issuance) of notes receivable		181,911		(50,390)
Purchase of intangible assets		(29,580)		–
Net cash (used in) investing activities		(67,132,921)		(3,253,675)

Cash flows from financing activities
Proceeds from issuance of debt, net		40,348,241		374,500
Repayment of notes payable		(5,000,000)		–
Proceeds from issuance of stock, net of issuance costs		50,282,798		–
Net cash provided by financing activities		85,631,039		374,500

Net (decrease) increase in cash and cash equivalents		19,893,534		(6,933,263)
Cash and cash equivalents at beginning of period		1,237,235		12,351,580
Cash and cash equivalents at end of period	$	21,130,769	$	5,418,317

Supplemental disclosure of cash flow information:
Cash paid for interest	$	2,131,495	$	–

See accompanying notes to the financial statements

MEDICINE MAN TECHNOLOGIES, INC.
Adjusted EBITDA Reconciliation
Non-GAAP measurement
(UNAUDITED)
For the Three Months Ended June 30, 2021
Expressed in U.S. Dollars

	Three Months Ended June 30, 2021
	2021		2020

Operating Income	$	4,440,915	$	(6,349,961)

Addbacks:
Non- Cash Stock Compensation	1,153,018		3,109,091
Deal Related Expenses	916,471		2,245,683
Capital Raise Related Expenses	230,970		(19,062)
Depreciation and Amortization	3,016,579		91,084
Severance	125,826		103,785
Retention Program Expenses	29,687		–
Employee Relocation Expenses	18,391		25,490
Other non-recurring items	90,012		–
Total Addbacks	5,580,954		5,556,071

Adjusted EBITDA	$	10,021,869	$	(793,890)

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “estimates”, “predicts,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses and realize synergies therefrom, (ix) the actual revenues derived from the Company’s Star Buds assets, * the Company’s actual revenue and adjusted EBITDA for 2021, (xi) the Company’s ability to generate positive cash flow for the rest of 2021 (xii) the ongoing COVID-19 pandemic, (xiii) the timing and extent of governmental stimulus programs, and (xiv) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

SOURCE Medicine Man Technologies, Inc.

SPACtrac – Virtual Roadshow with AeroFarms CEO David Rosenberg & CFO Guy Blanchard

Posted on August 16, 2021 by Admin

AeroFarms CEO David Rosenberg and CFO Guy Blanchard make a formal corporate presentation. Afterwards, they are joined by Noble Capital Markets Senior Research Analyst Joe Gomes for a Q & A session featuring questions asked by the live audience throughout the event.

SPACtrac report on AeroFarms

Information on upcoming live virtual roadshows

About AeroFarms

Since 2004, AeroFarms has been leading the way for indoor vertical farming and championing transformational innovation for agriculture. On a mission to grow the best plants possible for the betterment of humanity, AeroFarms is a Certified B Corporation with global headquarters in Newark, New Jersey. Named one of the World’s Most Innovative Companies by Fast Company two years in a row and one of TIME’s Best Inventions in Food, AeroFarms patented, award-winning indoor vertical farming technology provides the perfect conditions for healthy plants to thrive, taking agriculture to a new level of precision, food safety, and productivity while using up to 95% less water and no pesticides ever versus traditional field farming. AeroFarms enables local production to safely grow all year round, using vertical farming for elevated flavor. In addition, through its proprietary growing technology platform, AeroFarms has grown over 550 varieties and has developed multi-year strategic partnerships ranging from government to major Fortune 500 companies to help uniquely solve agriculture supply chain needs. For additional information, visit: https://aerofarms.com/.
On March 26, 2021, AeroFarms announced a definitive business combination agreement with Spring Valley Acquisition Corp. (Nasdaq: SV). Upon the closing of the business combination, AeroFarms will become publicly traded on Nasdaq under the new ticker symbol “ARFM”. Additional information about the transaction can be viewed here: https://aerofarms.com/investors/.

Comtech Telecommunications Corp. to Showcase 911 Solutions for States and Local Jurisdictions at APCO 2021

Posted on August 16, 2021 by Admin

Comtech Telecommunications Corp. to Showcase 911 Solutions for States and Local Jurisdictions at APCO 2021

MELVILLE, N.Y.–(BUSINESS WIRE)–Aug. 16, 2021–
August 16, 2021—
Comtech Telecommunications Corp. (NASDAQ: CMTL), a global leading provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today that it will be showcasing all of the Company’s Next Generation 911 (“NG911”) solutions
August 16-17 at the annual
Association of Public-Safety Communications Officials (“APCO”) Conference & Expo.

With decades of experience,
Comtech has developed an extensive portfolio of call routing, call handling, location data delivery and text messaging solutions and has strengthened its one-stop-shop NG911 capabilities for states and local jurisdictions.
Comtech is the only company in the industry offering a one-stop-shop next-generation 911 approach that includes comprehensive in-house capabilities that cross the entire deployment and ongoing systems management.

Located at the
Henry B. Gonzalez Convention Center in
San Antonio, TX,
Comtech invites attendees to visit booth 801, meet its team of 911 industry experts, and learn more about the following:

Call Routing and Location Delivery:
Comtech designs, implements, and operates secure, highly available, carrier agnostic Emergency Services IP Networks (“ESInets”) across
the United States. Our standards-based NG911 Next Generation Core Services (“NGCS”) applications enable end-to-end Internet Protocol (“IP”) call completion and data delivery.
Call Handling and Management Solutions: Purpose-built with more than 30 years of research and innovation, Solacom’s Guardian line of 911 solutions are advanced hardware and software technologies trusted to streamline processes and enable a more efficient collection of critical information in emergency situations. Live demonstrations for our industry-leading 911 solutions include Guardian Call Handling, Guardian Map, and our latest workload planning and management application, Guardian Insights.
Cybersecurity: Comtech’s cyber solutions include up-skill, re-skill, and training systems to increase the cybersecurity skills of any mission critical workforce or public safety staff. These solutions provide education, hands-on training, and live online knowledge assessment and skills-building programs in all cybersecurity areas.
Situational Awareness: Comtech’s situational awareness platform is an in-cloud geospatial solution with real time, contextual, and actionable intelligence for public safety answering points (“PSAPs”) and security agencies. This powerful application collates human and device-generated data into a flexible mapping interface, providing actionable insights into emergency situations for efficient and effective management of crisis situations.
Text Messaging Capabilities:
Comtech offers multiple options for Text to 911, including an interim web-based solution (“EMedia®”) and Session Initiation Protocol (“SIP”) Message Session Relay Protocol (“MSRP”) connectivity from the
Comtech Text Control Center (“TCC”) to PSAPs’ call handling equipment (“CHE”). Additionally, Guardian Text—an integrated, standards-based, full-featured short message service (“SMS”) function for Text to 911 and Text from 911—seamlessly integrates full text management capabilities into our Guardian 911 Call Handling solution and allows call takers to respond quickly and easily.

About Comtech

Comtech Telecommunications Corp. is a leading provider of next-generation 911 emergency systems and critical wireless communication technologies to commercial and government customers around the world. Headquartered in
Melville, New York and with a passion for customer success,
Comtech designs, produces and markets advanced and secure wireless solutions to customers in more than 100 countries. For more information, please visit www.comtechtel.com.

Forward-Looking Statements

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such
Securities and Exchange Commission filings.

Comtech Investor Relations:
631-962-7005
investors@comtech.com

Source:
Comtech Telecommunications Corp.

Release – Gevo Releases IMPACT an Environmental Social and Corporate Governance Report

Posted on August 16, 2021 by Admin

Gevo Releases IMPACT, an Environmental, Social, and Corporate Governance (ESG) Report; Strengthening its Commitment to Transparency and Accountability

ENGLEWOOD, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) has published IMPACT, a sustainability report which demonstrates Gevo’s mission to be transparent on its environmental, social, and corporate governance (ESG) performance. In addition to disclosing Gevo’s progress in 2020 and goals for the future, IMPACT shares details about Gevo’s holistic approach to commercializing high-value nutritional products and groundbreaking energy-dense, renewable transportation fuels. The report demonstrates Gevo’s environmental stewardship, workplace culture and social inclusivity, and internal leadership. It also fosters a deeper understanding of stakeholder needs, generates opportunities for long-term sustainable capital, and bolsters a drive for continuous improvement.

Gevo’s Chief Executive Officer, Dr. Patrick Gruber, has expressed his support for this progressive and comprehensive sustainability report: “We have a way of transforming renewable energy into energy-dense liquids. As we do that, we pay attention to the whole picture; we intend to track it, make it incredibly transparent. The ESG report is an important part of that effort. It’s also about our employees. We care about diversity in our workforce and bringing in the best skill sets we possibly can across the board. We are going to be a global company, and so for us, it’s incredibly important to build up our diversity in our workforce.”

IMPACT forecasts an exciting future for Gevo. In conjunction with Gevo’s pledge to reduce greenhouse gas (GHG) emissions for customers, the company is passionate about lowering the carbon footprint of internal systems and products. IMPACT also demonstrates the Board of Directors’ strong governance role in the effort to fight climate change. Gevo believes its technology and systems approach will improve the environment and deliver social benefits to the wider world and IMPACT provides a greater perspective on how the company plans to deliver those benefits.

To view the full IMPACT report, please visit: https://gevo.com/impact-2020/

About Gevo

Gevo is commercializing the next generation of gasoline, jet fuel and diesel fuel with the potential to achieve zero carbon emissions, addressing the market need of reducing greenhouse gas emissions with sustainable alternatives. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low carbon products such as gasoline components, jet fuel, and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business. Learn more at www.gevo.com.

About ESG Reporting

According to NASDAQ’s ESG reporting guides, ESG generally refers to “a broad set of environmental, social and corporate governance considerations that may impact a company’s ability to execute its business strategy and create value over the long term,” and ESG reports are a vital and progressive tool for assessing publicly-traded companies. Since 2011, there has been a dramatic increase in sustainable reporting from corporate entities. In its 2020 analysis, the Governance & Accountability Institute (G&A) found that 90% of companies in the S&P 500 published an ESG report. This illustrates an increased demand from both investors and business leaders for transparency, safety, and fairness in the corporate sector.

IMPACT provides qualitative examples for relevant topics in the United Nations (UN) Sustainable Development Goals (SDG). The contents are also informed by the Sustainability Accounting Standards Board (SASB) Biofuels Industry Standard and the SASB Agricultural Products Industry Standard. Gevo continues to assess stakeholders’ interest in other frameworks such as the Task Force on Climate-related Financial Disclosures (TCFD) and may expand said reporting in the future. Unless otherwise noted, the report discloses activities and results for operated assets from January 1, 2020, to December 31, 2020.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, without limitation, including the publication of Gevo’s ESG report, the statements contained in Gevo’s ESG report, Gevo’s sustainability practices, Gevo’s products, Gevo’s technology, and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made ith the U.S. Securities and Exchange Commission by Gevo.

Investor and Media Contact
IR@gevo.com
+1 720-647-9605

Release – Comtech Telecommunications Corp. Awarded $1.7 Million Contract for COMET Terminals

Posted on August 16, 2021 by Admin

Comtech Telecommunications Corp. Awarded $1.7 Million Contract for COMET Terminals

MELVILLE, N.Y.–(BUSINESS WIRE)–Aug. 16, 2021–
August 16, 2021—
Comtech Telecommunications Corp. (NASDAQ: CMTL), a global leading provider of next-generation 911 emergency systems and secure wireless communications technologies, announced today, that during its fourth quarter of fiscal 2021, a non-
U.S.
NATO military customer awarded
Comtech a
$1.7 million contract for multiple COMET terminals. This represents the second procurement of COMET terminals by a non-
U.S.
NATO military customer, in additional to the multiple COMET terminals already procured by
U.S. Special Operations Command (“SOCOM”).

COMET, which stands for
Compact Over-the-horizon Mobile Expeditionary Terminal, is a rapidly deployable, low power, airline checkable, medium range, OTH microwave troposcatter terminal. COMET is ideally suited for situations where high bandwidth backhaul communications are required, extending critical services into areas where there is no communications infrastructure, or the infrastructure has been destroyed.

“We are extremely pleased to witness the adoption of COMET by
NATO partner militaries,” said Fred Kornberg, Chairman of the Board and Chief Executive Officer of
Comtech Telecommunications Corp. “We sense strong market demand for our COMET terminal and look forward to additional COMET orders in the future, from both
U.S. military and international customers.”

The contract was awarded to
Comtech Systems, Inc. (www.comtechsystems.com) which specializes in system design, integration, supply and commissioning of turnkey communication systems including over-the-horizon microwave, line-of-sight microwave, and satellite.

Comtech Investor Relations:
631-962-7005
investors@comtech.com

Source:
Comtech Telecommunications Corp.

Release – Sierra Metals Announces Update Of 10000 Tonnes Per Day Positive Preliminary Economic Assessment Results

Posted on August 16, 2021 by Admin

Sierra Metals Announces Update Of 10,000 Tonnes Per Day Positive Preliminary Economic Assessment Results To Now Include Iron Ore Production At Its Bolivar Mine In Mexico

TORONTO–(BUSINESS WIRE)– Sierra Metals Inc. (TSX: SMT) (BVL: SMT) (NYSE AMERICAN: SMTS) (“Sierra Metals” or “the Company”) is pleased to report the results of an updated Preliminary Economic Assessment (“PEA”) regarding the Company’s Bolivar Mine, located in Chihuahua State, Mexico to now include iron ore concentrate production.

This PEA report was prepared as a National Instrument 43-101 Technical Report for Sierra Metals Inc. (“Sierra Metals”) by SRK Consulting (Canada) Inc. (“SRK”). The full technical report will be filed on SEDAR within 45 days of this news release.

Highlights of the PEA include:

Updated After-tax Net Present Value (NPV): US$361 Million vs. US$283 Million previously at an 8% discount rate
The incremental benefit includes iron ore production and increasing production to 10,000 TPD from 5,000 TPD is now estimated to have an after-tax NPV (@8%) of US$78.2 million, an IRR of 69.0% vs. an NPV of US$57.4 million, and an IRR of 27.9% previously reported
Net After-tax Cash Flow: US$650 Million vs. US$521 Million previously
Life of Mine & Sustaining Capital Cost: US$345 Million
Total Operating Unit Cost: US$25.62/tonne and US$1.50/lb copper equivalent
Average LOM Copper Grade 0.72%
Average LOM Iron Ore Grade 13.5% from ROM ore, 15% from long term residues stockpile
Copper Price Assumption US$3.05/lb
Iron Ore Concentrate Price Assumption for 62% Fines US$75.90/DMT
MineLife: 14 years based on existing Mineral Resource Estimate
Life of Mine Copper Payable Production: 551 million pounds

Luis Marchese, CEO of Sierra Metals commented: “I am very encouraged by the results of this updated PEA now including iron ore production. As mentioned in the previous PEA published in October 2020, the value could be further increased by the potential sale of magnetite (iron ore) as a by-product. Today we are happy to report that we are confirming enhanced economics and improving the value of the Bolivar Mine. The economics in this PEA confirms the rationale for approving this project in April of this year, which is proceeding on a fast track basis.

Additional to the iron ore project, the plan is to profitably develop and grow the Bolivar Mine through accelerating staged increases to a production rate of 10,000 TPD in 2024 from today’s capacity of 5,000 TPD, based on current analysts consensus metal price estimates.

We are continuing with our strategy to increase the value of the Company on a per-share basis. This builds upon the demonstrated success we have shown with increases in our mineral resource base and working to improve the throughput at all mines. At the same time, we continue to use best practices to deal with the daily effects of COVID-19 on our workforce and communities. We expect these positive developments to improve profitability further and cash flow for the Company and all shareholders this coming year as well as in the future.”

Mineral Resource Estimate

The property is located in the Piedras Verdes District of Chihuahua State, Mexico, located approximately 250 kilometers southwest of the city of Chihuahua and consists of 14 mineral concessions (6,800 hectares). The Bolivar deposit is a Cu-Zn skarn and is one of many precious and base metal deposits of the Sierra Madre belt, which trends north-northwest across the states of Chihuahua, Durango, and Sonora in northwestern Mexico (Meinert, 2007). Mineralization exhibits strong stratigraphic control, and two stratigraphic horizons host the bulk of the mineralization: an upper calcic horizon, which predominantly hosts Zn-rich mineralization, and a lower dolomitic horizon, which predominantly hosts Cu-rich mineralization. In both cases, the highest grades are developed where structures and associated breccia zones cross these favorable horizons near skarn-marble contacts.

This PEA considers depleted measured, indicated, and inferred resources reported in 2019 by SRK and effective as of December 31, 2019. The results of this PEA shown in Table 1-1 are indicative of conceptual potential and are not definitive.

Table 1-1: Summary of Mineral Resources estimate as reported by SRK,2020(EffectiveDecember 31, 2019)

Class	Tonnes (Mt)	Ag (g/t)	Au (g/t)	Fe (%)	Cu (%)	Ag (M oz)	Au (k oz)	Cu (t)
Indicated	19.4	15.1	0.21	13.8	0.77	9.4	127.8	149,116
Inferred	21.4	14.2	0.21	13.5	0.78	9.8	145.6	167,077

Source: SRK, 2020

1) Mineral resources are not mineral reserves and do not have demonstrated economic viability.

2) All figures are rounded to reflect the relative accuracy of the estimates.

3) Mineral resources are reported at a value per tonne cut-off of US$24.25/t using the following
metal prices and recoveries; Cu at US$3.08/t and 88% recovery; Ag at US$17.82/oz and 78.6%
recovery, Au at US$1,354/oz and 62.9% recovery.

Mining Methodology

Bolivar is a producing operation. The primary mining method at Bolivar is underground room and pillar mining. Previous mining at Bolivar has sometimes used lower cost and more productive long hole stope mining in areas where the mineralized zones have a steeper dip angle. The mine plans are to undertake a geotechnical assessment program in 2020/2021 to expand the use of long-hole mining.

Mineral Processing

The Piedras Verdes Plant, located 5.1 kilometers from the Bolivar Mine, uses a conventional crushing-grinding-flotation circuit to recover mineralized ore and produce commercial-quality copper concentrates with silver and gold by-products credits. The mineralized ore is delivered from the mine to the plant in 18-tonne trucks. In addition, the mine is constructing an underground tunnel that will enable mineralized material to be delivered via underground truck transport to a portal adjacent to the mill. This development will eliminate the impact of bad weather on the current surface truck haulage system. In addition, it will provide a lower cost and more reliable method of delivering mineralized material to the plant.

Mineral processing and the recovery of the mineral are demonstrated, and copper, silver and gold recoveries are established at 88%, 78.7% and 62.43%, respectively.

The Piedras Verdes Plant’s current throughput capacity is 5,000 TPD. In line with proposed increases in mine output, the processing capacity at Piedras Verdes will increase to 10,000 TPD in 2024.

A new tailing storage facility (“TSF”) (herein referred to as “New TSF”) is to be located just to the west of the existing facility and has an expected life through 2025. The PEA considers the use of tailings as a backfill and has included the capital and operating costs for a backfill plant. Storing some of the tailings underground would increase the life of the New TSF, and potentially permit the removal of mineralized material pillars that are currently unrecoverable.

The overall Project infrastructure exists already and is functioning and adequate to support the mine and mill.

Economic Analysis

This PEA indicates an after-tax NPV of US$361million (using a discount rate of 8%) at 10,000 TPD (in 2024). The total operating cost for the life of mine is US$1,071 million, equating to a total operating cost of US$25.62 per tonne milled and US$1.50 per pound copper equivalent. Highlights of the PEA are provided in Table 1-2.

Table 1-2: PEA Highlights

Updated PEA Highlights Base case of $1,541/oz Gold, $20.00/oz Silver, $3.05/lb Copper, Iron Concentrate (62% Fe) $75.90/DMT.	Unit	Value
Net Present Value (After Tax 8% Discount Rate)	US$ M	361

LOM Mill Feed (ROM ore)	Tonnes (Mt)	41.8
LOM Mill Feed (residues stockpile)	Tonnes (Mt)	6.0
Mining Production Rate	t/year	3,600,000
LOM Project Operating Period	Years	14
Total Life of Mine (LoM) Capital Costs	US$ M	345
Net After – Tax Cashflow	US$ M	650
EBITDA	US$ M	1,299
Total Operating Unit Costs	US$/t	25.62
LOM Copper Production (Payable)	Mt	0.25
LOM Gold Production (Payable)	Moz	0.15
LOM Silver Production (Payable)	Moz	12.9
LOM Iron Concentrate Production, 62% Fe (Payable)	Mt	5.7

Quality Control

All technical data contained in this news release has been reviewed and approved by:

Americo Zuzunaga, FAusIMM CP (Mining Engineer) and Vice President of Corporate Planning is a Qualified Person under National Instrument 43-101 – Standards of Disclosure for Mineral Projects.

About Sierra Metals

Sierra Metals Inc. is a diversified Canadian mining company focused on the production and development of precious and base metals from its polymetallic Yauricocha Mine in Peru, and Bolivar and Cusi Mines in Mexico. The Company is focused on increasing production volume and growing mineral resources. Sierra Metals has recently had several new key discoveries and still has many more exciting brownfield exploration opportunities at all three Mines in Peru and Mexico that are within close proximity to the existing mines. Additionally, the Company also has large land packages at all three mines with several prospective regional targets providing longer-term exploration upside and mineral resource growth potential.

The Company’s Common Shares trade on the Bolsa de Valores de Lima and on the Toronto Stock Exchange under the symbol “SMT” and on the NYSE American Exchange under the symbol “SMTS”.

For further information regarding Sierra Metals, please visit www.sierrametals.com.

Continue to Follow, Like and Watch our progress:

Web: www.sierrametals.com | Twitter: sierrametals | Facebook: SierraMetalsInc | LinkedIn: Sierra Metals Inc | Instagram: sierrametals

Forward-Looking Statements

This press release contains “forward-looking information” and “forward-looking statements” within the meaning of Canadian and U.S. securities laws (collectively, “forward-looking information“). Forward-looking information includes, but is not limited to, statements with respect to the date of the 2020 Shareholders’ Meeting and the anticipated filing of the Compensation Disclosure. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “assumes”, “intends”, “strategy”, “goals”, “objectives”, “potential” or variations thereof, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking information.

Forward-looking information is subject to a variety of risks and uncertainties, which could cause actual events or results to differ from those reflected in the forward-looking information, including, without limitation, the risks described under the heading “Risk Factors” in the Company’s annual information form dated March 30, 2020 for its fiscal year ended December 31, 2019 and other risks identified in the Company’s filings with Canadian securities regulators and the United States Securities and Exchange Commission, which filings are available at www.sedar.com and www.sec.gov, respectively.

The risk factors referred to above are not an exhaustive list of the factors that may affect any of the Company’s forward-looking information. Forward-looking information includes statements about the future and is inherently uncertain, and the Company’s actual achievements or other future events or conditions may differ materially from those reflected in the forward-looking information due to a variety of risks, uncertainties and other factors. The Company’s statements containing forward-looking information are based on the beliefs, expectations and opinions of management on the date the statements are made, and the Company does not assume any obligation to update such forward-looking information if circumstances or management’s beliefs, expectations or opinions should change, other than as required by applicable law. For the reasons set forth above, one should not place undue reliance on forward-looking information.

Mike McAllister
Vice President, Investor Relations
Sierra Metals Inc.
Tel: +1 (416) 366-7777
Email: info@sierrametals.com

Americo Zuzunaga
Vice President of
Corporate Planning
Sierra Metals Inc.
Tel: +1 (416) 366-7777

Luis Marchese
CEO
Sierra Metals Inc.
Tel: +1 (416) 366-7777

Source: Sierra Metals Inc.

Release – Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates

Posted on August 16, 2021 by Admin

Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates

Influenza program Phase 1 clinical trial with CC-42344 on track to begin in the third quarter of 2021
COVID-19 program preclinical development with the novel oral SARS-CoV-2 protease inhibitors is advancing
Two IND-enabling studies in the COVID-19 program expected to begin in the first half of 2022 prior to Phase 1 clinical trials
$67 million in cash at quarter-end is expected to fund current operations beyond 2024

BOTHELL, Wash., Aug. 16, 2021 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company, reports financial results for the three and six months ended June 30, 2021, and provides updates on its antiviral pipeline, milestones and business activities.

“Our scientific team is rapidly advancing the discovery and development of novel antiviral compounds that are aimed at addressing unmet medical needs for antiviral therapeutics,” said Sam Lee, Ph.D., President and co-interim CEO of Cocrystal. “Our novel antivirals are intended to halt the replication of viruses that cause serious human diseases.

“We plan to initiate IND-enabling studies in the first half of 2022 with our SARS-CoV-2 protease inhibitor, CDI-45205, for intranasal/pulmonary delivery, as well as with a novel oral SARS-CoV-2 protease inhibitor that we discovered with our proprietary structure-based drug discovery technology. Our plan is to hold a pre-IND meeting with the FDA with CDI-45205 this year, followed by a pre-IND meeting with our novel oral inhibitor in the first half of 2022,” he added. “We are encouraged by recent in vitro laboratory data indicating CDI-45205 is highly active against the SARS-CoV-2 (Wuhan strain) as well as four variants of concern, including the Delta variant. We are also very excited by recent preclinical data with our SARS-CoV-2 oral inhibitors. We plan to initiate drug substance and drug product manufacturing with these oral inhibitors this year.

“We are on track this quarter to initiate a Phase 1 clinical trial in healthy volunteers with CC-42344, our lead compound being developed for the treatment of seasonal and pandemic influenza,” Dr. Lee concluded.

“We are in a good financial position at the second quarter with more than $67 million in cash and a clean balance sheet consisting of common stock only with no debt,” said James Martin, CFO and Co-Interim CEO. “We believe our capital is sufficient to fund planned operations beyond 2024, including clinical trials, as we advance toward commercialization.”

Antiviral Pipeline Overview

COVID-19 Programs

By targeting viral replication enzymes and proteases, Cocrystal believes it is possible to develop effective treatments for all coronaviruses including SARS-CoV-2, SARS-CoV and MERS-CoV.
CDI-45205 was among the broad-spectrum viral protease inhibitors obtained from Kansas State University Research Foundation (KSURF) under an exclusive license agreement announced in 2020. Cocrystal entered into the KSURF agreements to enable the rapid advancement of COVID-19 programs.
CDI-45205 has demonstrated a strong in vitro synergistic effect with the FDA-approved COVID-19 medicine remdesivir.
Proof-of-concept data demonstrated that daily injections of CDI-45205 exhibited favorable in vivo efficacy in mice infected with MERS-CoV-2.

Influenza A Program

The Phase 1 clinical study with CC-42344 is expected to be conducted in Australia, which offers favorable regulatory policies and a clinical trial environment that aligns with the Company’s strategy for rapid, cost-efficient and high-quality clinical development.
CC-42344 showed broad-spectrum and potent antiviral activity against influenza A strains, including avian pandemic strains, Tamiflu- and Xofluza-resistant strains, along with a favorable pharmacokinetic profile.
Influenza remains a major global concern. An influenza pandemic is a global outbreak of new influenza A virus. According to the World Health Organization (WHO) there are approximately 1 billion cases of influenza annually worldwide, resulting in 3 million to 5 million cases of severe illness and 250,000 to 500,000 deaths.

Norovirus Program

Cocrystal is developing certain proprietary broad-spectrum antiviral compounds to treat norovirus infections under its license agreement with KSURF.
Norovirus is a public health problem responsible for nearly 90% of epidemic, non-bacterial outbreaks of gastroenteritis around the world.

Hepatitis C Program

Cocrystal is seeking a partner to advance the development of CC-31244 following completion of a Phase 2a trial. This compound showed favorable safety and preliminary efficacy in a triple regimen Phase 2a study in combination with Epclusa (sofosbuvir/velpatasvir) for the ultra-short duration treatment of individuals infected with the hepatitis C virus (HCV). To date, no other company has developed an HCV treatment of 4 weeks or less with a high (>95%) sustained virologic response at Week 12.
HCV is a viral infection of the liver that causes both acute and chronic infection. According to the WHO, in 2017 an estimated 71 million people worldwide had chronic HCV infection, including 3.5 million in the U.S. Approximately 399,000 people die each year from hepatitis C infection, mostly from cirrhosis and hepatocellular carcinoma.

Second Quarter 2021 and Recent Corporate Highlights

Designated President Dr. Lee and CFO Martin as Co-Interim CEOs, following the unexpected passing of Chairman, CEO and co-founder Dr. Gary Wilcox. Roger Kornberg, Ph.D., co-founder, Chief Scientist, Director and Chairman of the Scientific Advisory Board, was named Chairman of the Board, and Steve Rubin, Director of Cocrystal and its predecessor company since 2008, was named Vice Chairman.
Raised $36.4 million in net proceeds from a public offering of common stock in May 2021.
Cocrystal common stock was added to the Russell Microcap^® Index, a broadly used performance measure for smaller growth stocks in the U.S.

Second Quarter Financial Results

Throughout 2020 Cocrystal reported quarterly revenues under an influenza A/B collaboration with Merck consisting of research and development (R&D) services performed by Cocrystal and reimbursed by Merck. In January 2021 Merck assumed all activities and expenses associated with the continued development of the influenza A/B compounds discovered under this collaboration. As anticipated, Cocrystal reported no revenues for the second quarter of 2021 compared with $554,000 in revenues for the second quarter of 2020. Under the terms of the Merck collaboration, Cocrystal is eligible to receive up to $156 million in future payments related to designated developments, regulatory and sales milestones, as well as royalties on product sales.

R&D expenses for the second quarter of 2021 were $2.7 million compared with $2.0 million for the second quarter of 2020, with the increase primarily related to higher spending on the COVID-19 and influenza programs. The Company expects R&D expenses to increase in the second half of 2021 with the initiation of a clinical trial in the influenza A program and advancements with the COVID-19 programs toward clinical development. General and administrative (G&A) expenses for the second quarter of 2021 were $1.1 million versus $2.0 million for the prior-year quarter, with the decline primarily due to reduced professional fees.

The net loss for the second quarter of 2021 was $3.8 million, or $0.04 per share, compared with a net loss for the second quarter of 2020 of $3.5 million, or $0.07 per share.

Year to Date Financial Results

The Company did not report revenues for the first six months of 2021 versus $1.0 million for the first six months of 2020. The 2020 revenues were reimbursement for R&D services performed under the influenza A/B program with Merck. In January 2021, the influenza A/B program was advanced for continued development of the antiviral agents at Merck. Merck is responsible for funding continued development of the compounds.

R&D expenses for the first half of 2021 increased 33% to $4.3 million and G&A expenses decreased 29% to $2.2 million, both compared with the first six months of 2020. The increased R&D in 2021 was primarily due to development of COVID-19 programs and preparation to advance our influenza A program into clinical trials.

The net loss for the six months ended June 30, 2021 was $6.6 million, or $0.08 per share, compared with a net loss for the six months ended June 30, 2020 of $5.5 million, or $0.12 per share.

The Company reported cash and cash equivalents of $67.1 million as of June 30, 2021 compared with $33.0 million as of December 31, 2020. The Company reported working capital of $65.0 million as of June 30, 2021.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected advancement of our antiviral programs, including the planned initiation of the influenza A Phase 1 study during the third quarter of 2021, the planned pre-IND meetings with the FDA and the expected initiation of two IND-enabling studies in the COVID-19 program in the first half of 2022 and subsequent Phase 1 clinical trials, the anticipated initiation of SARS-CoV-2 oral inhibitors manufacturing in 2021; our expectations and estimates regarding the future applications and effectiveness of, and the market opportunities for, our product candidates; our expectations related to conducting clinical trials in Australia; our expectations regarding future operating results; the expected results of Cocrystal’s collaboration with Merck, including potential receipt of future milestone payments of up to $156 million and royalties; ; and future liquidity. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from the impact of the COVID-19 pandemic on the national and global economy, on our collaboration partners, CROs, CMOs, and on our Company, including raw material and test animal shortages and other supply chain disruptions, the ability of our CROs to recruit volunteers for, and to proceed with, clinical trials, possible delays resulting from the lockdown in Australia, the cooperation of the FDA in accelerating development in our COVID-19 program, our reliance on Merck for further development in the influenza A/B program under the license and collaboration agreement, our collaboration partners’ technology and software performing as expected, the results of future preclinical and clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com

Financial Tables to follow

COCRYSTAL PHARMA, INC.

CONSOLIDATED BALANCE SHEETS
(in thousands)

	June 30, 2021			December 31, 2020
		(unaudited)
Assets
Current assets:
Cash	$	67,062		$	33,010
Restricted cash		50			50
Accounts receivable		–			556
Prepaid expenses and other current assets		225			399
Total current assets		67,337			34,015
Property and equipment, net		539			591
Deposits		46			46
Operating lease right-of-use assets, net (including $10 to related party)		403			498
Goodwill		19,092			19,092
Total assets	$	87,417		$	54,242
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and accrued expenses	$	2,138		$	1,080
Current maturities of finance lease liabilities		33			39
Current maturities of operating lease liabilities (including $10 to related party)		157			178
Derivative liabilities		51			61
Total current liabilities		2,379			1,358
Long-term liabilities:
Finance lease liabilities		21			34
Operating lease liabilities		269			345
Total long-term liabilities		290			379
Total liabilities		2,669			1,737
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.001 par value; 100,000 shares authorized as of June 30, 2021 and December 31, 2020, respectively; 97,469 and 70,439 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively		98			71
Additional paid-in capital		336,117			297,342
Accumulated deficit		(251,467	)		(244,908	)
Total stockholders’ equity		84,748			52,505
Total liabilities and stockholders’ equity	$	87,417		$	54,242

COCRYSTAL PHARMA, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)


	Three months ended June 30,						Six months ended June 30,
	2021			2020			2021			2020

Revenues:
Collaboration revenue	$	–		$	554		$	–		$	1,015
		–			554			–			1,015
Operating expenses:
Research and development		2,747			1,976			4,324			3,259
General and administrative		1,081			2,028			2,242			3,167
Total operating expenses		3,828			4,004			6,566			6,426

Loss from operations		(3,828	)		(3,450	)		(6,566	)		(5,411	)

Other income (expense):
Interest expense, net		(2	)		(2	)		(3	)		(4	)
Change in fair value of derivative liabilities		9			(43	)		10			(70	)
Total other income (expense), net		7			(45	)		7			(74	)
Net loss	$	(3,821	)	$	(3,495	)	$	(6,559	)	$	(5,485	)

Net loss per common share, basic and diluted	$	(0.04	)	$	(0.07	)		(0.08	)		(0.12	)
Weighted average number of common shares outstanding, basic and diluted		87,069			52,141			79,116			46,930

Source: Cocrystal Pharma, Inc.

Release – Capstone Green Energys United Kingdom Integrated Remanufacturing Facility Expands its Global Remanufacturing Training and Support Capabilities

Posted on August 16, 2021 by Admin

Capstone Green Energy’s United Kingdom Integrated Remanufacturing Facility Expands its Global Remanufacturing, Training, and Support Capabilities

VAN NUYS, CA / ACCESSWIRE / August 16, 2021 / Capstone Green Energy Corporation (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN), formerly Capstone Turbine Corporation (www.capstoneturbine.com) (NASDAQ:CPST) (“Capstone” or the “Company”), announced today the completion of the grid interconnect expansion at the UK Integrated Remanufacturing Facility which allows for the building and testing of Capstone’s C200 engines. Expanding the operations at the UK facility is fundamental for the long term support of Capstone’s established and growing sustainable energy fleet in the EMEA (Europe, Middle East & Africa) region.

Located a short distance south of London and close to UK’s major shipping infrastructure, Capstone’s strategically located Gosport facility plays an increasingly important role in supporting the growth and expansion of the global microturbine fleet, as well as the rental program, which is a critical component of the Company’s Energy as a Service (EaaS) business line. The construction of individual test cells and an increased grid export capacity agreement of 500kW marks a significant milestone in the UK operation’s expanded capability to remanufacture C200 powerheads, in addition to remanufacturing the C200 recuperators.

From an original footprint of 3,000 square feet in 2009 to the current 19,000 square feet expanded facility, the UK operation has evolved from a warehouse for aftermarket parts and hub for field support, to a fully integrated remanufacturing facility capable of serving the EMEA region’s future build requirements for Capstone’s flagship C200 engines. Taking recent possession of the adjacent building also marks the start of a trade-in program for a region with a legacy fleet to upgrade to the more efficient Signature Series product. The added floor space will accommodate a state-of-the-art training suite for in classroom and hands-on training for regional Distributors fulfilling their need to reduce travel costs while staying product-current and maintaining vital coverage.

“Continuing to invest in our UK operation is critical to Capstone’s key objectives to reduce and drive down freight dependency and offset manufacturing costs through our remanufacturing program. In parallel, we are improving response times for all our existing Distributor partners and growing our Energy as a Service (EaaS) business as we expand the global rental fleet,” said Darren Jamison, Capstone’s President and Chief Executive Officer “By adding complex remanufacturing processes, the UK facility now mirrors the Capstone US-based testing facilities. These capabilities will accelerate Capstone’s ability to provide parts and services to EMEA and improve future aftermarket margins” added Mr. Jamison.

“The ability to remanufacture in the UK has proven invaluable for the region, so executing the plan to maximize capability through engine builds and staging rental growth is the next natural step,” said Tracy Chidbachian, Capstone Director of Customer Service. “Led by Jim Newbold, our Director of Global Services, the UK’s highly experienced and talented team plays a vital role in Capstone’s broader support plan and strategic development for the region,” concluded Ms. Chidbachian.

About Capstone Green Energy

Capstone Green Energy (www.CapstoneGreenEnergy.com) (NASDAQ:CGRN) is a leading provider of customized microgrid solutions and on-site energy technology systems focused on helping customers around the globe meet their environmental, energy savings, and resiliency goals. Capstone Green Energy focuses on four key business lines. Through its Energy as a Service (EaaS) business, it offers rental solutions utilizing its microturbine energy systems and battery storage systems, comprehensive Factory Protection Plan (FPP) service contracts that guarantee life-cycle costs, as well as aftermarket parts. Energy Conversion Products are driven by the Company’s industry-leading, highly efficient, low-emission, resilient microturbine energy systems offering scalable solutions in addition to a broad range of customer-tailored solutions, including hybrid energy systems and larger frame industrial turbines. The Energy Storage Products business line designs and installs microgrid storage systems creating customized solutions using a combination of battery technologies and monitoring software. Through Hydrogen Energy Solutions, Capstone Green Energy offers customers a variety of hydrogen products, including the Company’s microturbine energy systems.

For customers with limited capital or short-term needs, Capstone offers rental systems; for more information, contact: rentals@CGRNenergy.com. To date, Capstone has shipped over 10,000 units to 83 countries and estimates that, in FY21, it saved customers over $217 million in annual energy costs and approximately 397,000 tons of carbon. Total savings over the last three years are estimated at 1,115,100 tons of carbon and $698 million in annual energy savings.

For more information about the Company, please visit: www.CapstoneGreenEnergy.com. Follow Capstone Green Energy on Twitter, LinkedIn, Instagram, Facebook, and YouTube.

Cautionary Note Regarding Forward-Looking Statements

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including statements regarding expectations for green initiatives and execution on the Company’s growth strategy and other statements regarding the Company’s expectations, beliefs, plans, intentions, and strategies. The Company has tried to identify these forward-looking statements by using words such as “expect,” “anticipate,” “believe,” “could,” “should,” “estimate,” “intend,” “may,” “will,” “plan,” “goal” and similar terms and phrases, but such words, terms and phrases are not the exclusive means of identifying such statements. Actual results, performance and achievements could differ materially from those expressed in, or implied by, these forward-looking statements due to a variety of risks, uncertainties and other factors, including, but not limited to, the following: the ongoing effects of the COVID-19 pandemic; the availability of credit and compliance with the agreements governing the Company’s indebtedness; the Company’s ability to develop new products and enhance existing products; product quality issues, including the adequacy of reserves therefor and warranty cost exposure; intense competition; financial performance of the oil and natural gas industry and other general business, industry and economic conditions; the Company’s ability to adequately protect its intellectual property rights; and the impact of pending or threatened litigation. For a detailed discussion of factors that could affect the Company’s future operating results, please see the Company’s filings with the Securities and Exchange Commission, including the disclosures under “Risk Factors” in those filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

CONTACT:

Capstone Green Energy
Investor and investment media inquiries:
818-407-3628
ir@CGRNenergy.com

SOURCE: Capstone Green Energy Corporation

Helius Medical Technologies (HSDT)(HSM:CA) – Reports 2Q21 Results U.S. Efforts Ongoing

Posted on August 16, 2021 by Admin

Monday, August 16, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
Reports 2Q21 Results; U.S. Efforts Ongoing

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q21 Results. Canadian COVID related restrictions continue to impact Helius operating results. Helius reported 2Q revenue of $71,000 down from $84,000 in 1Q21. Net loss for the quarter including $2.6 million of stock-based compensation expense was $6.0 million, or $2.58 per share, compared to a net loss of $3.6 million, or $2.90 per share last year. We had forecast revenue of $90,000 and a net loss of $3.6 million, or $1.53 per share.

U.S. Commercialization Efforts Ongoing. Helius continues to develop a plan for U.S. commercialization of the PoNS Treatment. The Company recently hired a new VP of Sales & Marketing for North America, Fred Fantazzia, an expert in developing the market for new neuromodulation technologies. State approvals rose to 43 from 24 at the end of 1Q21. The Company has refined its initial target market to 10 …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Gevo Inc. (GEVO) – Net Zero One Engineering and RNG Plant Moving Ahead

Posted on August 16, 2021 by Admin

Monday, August 16, 2021

Gevo, Inc. (GEVO)
Net Zero One Engineering and RNG Plant Moving Ahead

Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment and the Gevo Development/Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of isobutanol, including the development of its biocatalysts, the production and sale of biojet fuel, its Retrofit process and the next generation of chemicals and biofuels that will be based on its isobutanol technology. Gevo Development/Agri-Energy is the key revenue generating segment which involves the operation of the Luverne Facility and production of ethanol, isobutanol and related products.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

EBITDA losses continued in 2Q2021, but cash higher due to RNG plant financing. Given the stage of development of the renewable fuels concept, it isn’t surprising that EBTDA was negative $17.1 million due to higher development costs. We expect negative EBITDA to continue into at least next year. Cash increased $567 million from $525 million in 1Q2021 due to RNG debt financing of $69 million which was partially offset by the quarterly cash burn.

RNG plant financed and under construction. BP identified as the customer. In 2Q2021, 1.5% debt financing of $69 million for the renewable natural gas (RNG) plant in NE Iowa was finalized. Construction began and capex will be reimbursed from funds held in trust over the next three quarters. BP is the customer, which is a positive …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Palladium One Corporate Update

Michael Burry vs Cathie Wood is Not an Even Competition

Index Funds May Still Fall Apart Over Time

Is the Index Bubble Michael Burry Warned us About Still Looming?

Michael Burry Tweets Advice on Cryptocurrency

Michae Burry Says Covid Cure Worse Than Disease

Noble Capital Markets Uranium Power Players Investor ForumAugust 31, 2021

Schwazze Announces Second Quarter Results

SPACtrac report on AeroFarms

Information on upcoming live virtual roadshows

Comtech Telecommunications Corp. to Showcase 911 Solutions for States and Local Jurisdictions at APCO 2021

Gevo Releases IMPACT, an Environmental, Social, and Corporate Governance (ESG) Report; Strengthening its Commitment to Transparency and Accountability

Comtech Telecommunications Corp. Awarded $1.7 Million Contract for COMET Terminals

Sierra Metals Announces Update Of 10,000 Tonnes Per Day Positive Preliminary Economic Assessment Results To Now Include Iron Ore Production At Its Bolivar Mine In Mexico

Cocrystal Pharma Reports Second Quarter 2021 Financial Results and Provides Antiviral Program and Milestone Updates

Capstone Green Energy’s United Kingdom Integrated Remanufacturing Facility Expands its Global Remanufacturing, Training, and Support Capabilities

Helius Medical Technologies (HSDT)(HSM:CA)Reports 2Q21 Results; U.S. Efforts Ongoing

Gevo, Inc. (GEVO)Net Zero One Engineering and RNG Plant Moving Ahead

Noble Capital Markets Uranium Power Players Investor Forum
August 31, 2021

Helius Medical Technologies (HSDT)(HSM:CA)
Reports 2Q21 Results; U.S. Efforts Ongoing

Gevo, Inc. (GEVO)
Net Zero One Engineering and RNG Plant Moving Ahead